Rheumatology Research

A 15-year report of indications, adverse events, and effectiveness of therapeutic plasma exchange in patients with rheumatic diseases

Document Type : Original Article

Authors

1 Department of Internal Medicine, Division of Rheumatology, Shiraz University of Medical Science, Shiraz, Iran.

2 Department of Internal Medicine , Shiraz University of Medical Science, Shiraz ,Iran

10.32592/RR.2024.9.2.93

Abstract

Therapeutic plasma exchange (TPE) is a type of treatment, which eliminates harmful antibodies, immune complexes, cytokines, and inflammatory products. Due to the lack of sufficient data on indications, effectiveness, and side effects of TPE in patients with rheumatic disease, we evaluated TPE in our center. All consecutive patients registered in university hospitals with definite rheumatologic indications for TPE during 15 years were evaluated. 680 sessions of TPE were performed on 166 patients, aged between 19 and 83 years. The most common underlying causes were collagen vascular diseases (60%) including systemic lupus erythematosus (SLE) (98%), and antiphospholipid antibody syndrome (APS) (1%); and then, primary small vessel vasculitis (SVV) (39.8%). The main indications for TPE in all patients were rapidly progressive glomerulonephritis (RPGN) (69.8%) and pulmonary hemorrhage (39.1%). During 12 months follow-up, in SLE and SVV patients 17 (17.3%) and 20 (30.3%) entered complete remission; 37 (37.3%) and 12 (18.1%) entered partial remission; 44 (44.8%) and 34 (51.5%) had no recovery; and 37(37%) and 19 (28.7%) died, respectively. A total of 18 (10.8%) patients experienced TPE-related adverse events during TPE [hypotension 15 (9%), allergic reaction 1 (0.6%), fever 1 (0.6%), and hypocalcemia 1 (0.6%)]. The most common indication for TPE is SLE and primary vasculitis. The RPGN and pulmonary hemorrhage were the main indications. Although the rate of response to treatment was acceptable according to the fatal nature of these complications, further case-control studies are suggested to assess the effectiveness of TPE. 

Keywords

Main Subjects

References
1- Sergent SR, Ashurst JV. Plasmapheresis. [Updated 2023 Jul 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560566/
2- Fernández-Zarzoso M, Gómez-Seguí I, de la Rubia J. Therapeutic plasma exchange: Review of current indications. Transfus Apher Sci 2019; 58(3):247-53. doi: 10.1016/ j.transci.2019.04.007.
3- Udani MM, Neogi AJ, Dhote SW, Singh I. Therapeutic Plasma Exchange – A 2 years experience at a tertiary care centre in Mumbai, Maharashtra, India. J Evol Med Dent Sci 2021. DOI: 10.14260/jemds/ 2021/228
4- Lockwood CM, Pussell B, Wilson CB, Peters DK. Plasma exchange in nephritis. Adv Nephrol Necker Hosp 1979; 8:383-418.
5- Kaplan AA. Therapeutic plasma exchange: a technical and operational review. J Clin Apher 2013; 28(1):3-10. doi: 10.1002/jca. 21257.
6- Fernandez J, Gratacos-Ginès J, Olivas P, Costa M, Nieto S, Mateo D. et al. Plasma exchange: An effective rescue therapy in critically ill patients with coronavirus disease 2019 infection. Crit Care Med 2020; 48(12):e1350-e55. doi: 10.1097/ccm.00000 00000004613.
7- Honore PM, Redant S, Kugener L, Barreto Gutierrez L, Attou R, Gallerani A. et al. Plasma exchange dramatically reduced inflammatory markers, including main cytokines, ferritin, triglycerides, and d-dimers, thereby improving clinical outcomes: The true reality is far more complex! Crit Care Med 2021; 49(4):e485-e86. doi: 10.1097/ccm.0000000000004837.
8- Toyoda T, Yates M, Watts RA. Is there still a role of plasma exchange in the current management of ANCA-Associated Vasculitides? Curr Rheumatol Rep 2022; 24(4):111-17. doi: 10.1007/s11926-022- 01064-8.
9- Danieli MG, Palmieri C, Salvi A, Refe MC, Strusi AS, Danieli G. Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis. J Clin Apher 2002; 17(2):72-7. doi: 10.1002/jca.10020.
10- Huang DF, Tsai ST, Wang SR. Recovery of both acute massive pulmonary hemorrhage and acute renal failure in a systemic lupus erythematosus patient with lupus anticoagulant by the combined therapy of plasmapheresis plus cyclophosphamide. Transfus Sci 1994; 15(3):283-8. doi: 10. 1016/0955-3886(94)90155-4.
11- Nesher G, Hanna VE, Moore TL, Hersh M, Osborn TG. Thrombotic micro-angiographic hemolytic anemia in systemic lupus erythematosus. Semin Arthritis Rheum 1994; 24(3):165-72. doi: 10.1016/0049-0172 (94)90072-8.
12- Jagdish K, Jacob S, Varughese S, David VG, Mohapatra A, Valson A. et al. Effect of Double Filtration Plasmapheresis on Various Plasma Components and Patient Safety: A Prospective Observational Cohort Study. Indian J Nephrol 2017; 27(5):377-83.doi: 10.4103/ijn.IJN_64_17.
13- Lu J, Zhang L, Xia C, Tao Y. Complications of therapeutic plasma exchange: A retrospective study of 1201 procedures in 435 children. Medicine (Baltimore) 2019; 98(50):e18308. doi: 10.1097/md.00000000 00018308.
14- Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR. et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64(8):2677-86. doi: 10.1002/art.34473.
15- Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa MC, Piette JC. et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003; 12(7):530-4. doi: 10.1191/0961203303lu394oa.
16- Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F. et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65(1):1-11. doi: 10.1002/art.37715.
17- Al Hamzi HA, Al-Mayouf SM, Al Shaikh AA, Al-Sheikh HA, Alshomar AA, Al Humaidan HA. et al. Early and late effects of therapeutic plasma exchange in patients with systemic lupus erythematosus and antineutrophil cytoplasmic antibody-associated vasculitis: A single-center experience. Saudi J Kidney Dis Transpl 2019; 30(4):775-80. doi: 10.4103/1319-2442.265452.
18- Bai Z, Chen Y, Dong L. Experience of therapeutic plasma exchange in rheumatic diseases: Albumin may be a suitable substitute for plasma. Arch Rheumatol 2021; 36(3):398-408. doi: 10.46497/Arch Rheumatol.2021.8447.
19- Aguirre-Valencia D, Naranjo-Escobar J, Posso-Osorio I, Macía-Mejía MC, Nieto-Aristizábal I, Barrera T. et al. Therapeutic plasma exchange as management of complicated systemic lupus erythematosus and other autoimmune diseases. Autoimmune Dis 2019; 2019:5350960. doi: 10.1155/2019/ 5350960.
20- Soyuöz A, Karadağ Ö, Karaağaç T, Kılıç L, Bilgen Ş A, Özcebe O. Therapeutic plasma exchange for refractory SLE: A comparison of outcomes between different sub-phenotypes. Eur J Rheumatol 2018; 5(1):32-36. doi: 10.5152/eurjrheum.2017. 17088.
21- Sengul Samanci N, Ayer M, Gursu M, Ar MC, Yel K, Ergen A. et al. Patients treated with therapeutic plasma exchange: a single center experience. Transfus Apher Sci 2014; 51(3):83-9. doi: 10.1016/j.transci. 2014.10.006.
22- Vellinga S, Verpooten GA, Janssen van Doorn K. Trends in therapeutic plasma exchange: a single-center evaluation. Int J Artif Organs 2013; 36(10):730-7. doi: 10. 5301/ijao.5000238.
23- Sutton DM, Nair RC, Rock G. Complications of plasma exchange. Transfusion 1989; 29(2):124-7. doi: 10. 1046/j.1537-2995.1989.29289146829.x.
24- Maxted AP, Connell R, Hussain F. Double filtration plasmapheresis - 10-year pediatric experience as an alternative to plasma exchange. Transfus Apher Sci 2020; 59(6):102928. doi: 10.1016/j.transci.2020. 102928.
25- Vucic S, Davies L. Safety of plasma-pheresis in the treatment of neurological disease. Aust N Z J Med 1998; 28(3):301- 5.doi: 10.1111/j.1445-5994.1998Tb01952.x.
26- Joode AA, Sanders JS, Smid WM, Stegeman CA. Plasmapheresis rescue therapy in progressive systemic ANCA‐associated vasculitis: single‐center results of stepwise escalation of immune-suppression. J Clin Apher 2014; 29(5):266-72.doi: 10.1002/jca.21318.
Rheumatology Research
Volume 9, Issue 2
April 2024
Pages 93-102
Files
Share
How to cite
Statistics